Viridian Therapeutics Prepares for Transformational 2026
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Business Wire
- Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track -- Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively -- IND submitted for half-life extended FcRn-inhibitor, VRDN-008; healthy volunteer (HV) data expected in 2H 2026 -- Unveiling new program targeting thyroid-stimulating hormone receptor (TSHR); IND expected Q4 2026 -- Cash position of approximately $888 million as of October 31, 2025 -- Company expects its current business plans to be funded through profitability - WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and anticipated catalysts for 2026.“F
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (NASDAQ:VRDN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics (NASDAQ:VRDN) had its price target lowered by analysts at Truist Financial Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]Yahoo! Finance
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 1/2/26 - Form 4
- 12/31/25 - Form 144
- 11/14/25 - Form SCHEDULE
- VRDN's page on the SEC website